Unigen Pharmaceuticals, Inc.
Records under this name other than patents Unigen Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Unigen Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,852,657 | Chromones as therapeutic agents Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,362,305 | Series of Skin Whitening (LIGHTENING) Compounds Formerly held In force · High confidence | In force | High confidence | |
| US 8,945,518 | Formulation of Dual Eicosanoid System and Cytokine System Inhibitors for Use in the Prevention and Treatment of Oral Diseases and Conditions Formerly held Term ended Term ended Oct 8, 2026 · Medium confidence | Term ended | Term ended Oct 8, 2026 | Medium confidence |
| US 9,655,940 | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent Formerly held Term ended Term ended May 19, 2026 · USPTO record | Term ended | Term ended May 19, 2026 | USPTO record |
| US 8,592,488 | Diarylalkanes as potent inhibitors of binuclear enzymes Formerly held Term ended Term ended Aug 31, 2025 · High confidence | Term ended | Term ended Aug 31, 2025 | High confidence |
| US 7,678,772 | 7-hydroxy chromones as potent antioxidants Formerly held Term ended Term ended Jul 2, 2025 · USPTO record | Term ended | Term ended Jul 2, 2025 | USPTO record |
| US 7,767,661 | Diarylalkanes as Potent Inhibitors of Binuclear Enzymes Formerly held Term ended Term ended May 27, 2025 · High confidence | Term ended | Term ended May 27, 2025 | High confidence |
| US 7,674,830 | Formulation of a mixture of free-B-ring flavonoids and flavans as a therapeutic agent Formerly held Term ended Term ended Apr 2, 2025 · USPTO record | Term ended | Term ended Apr 2, 2025 | USPTO record |
| US 7,514,469 | Formulation of a mixture of Free-B-ring flavonoids and flavans as a therapeutic agent Formerly held Term ended Term ended Jul 3, 2024 · USPTO record | Term ended | Term ended Jul 3, 2024 | USPTO record |
| US 8,790,724 | Formulation of Dual Cycloxygenase (COX) and Lipoxygenase (LOX) Inhibitors for Mammal Skin Care Formerly held Term ended Term ended Apr 2, 2024 · High confidence | Term ended | Term ended Apr 2, 2024 | High confidence |